Newsroom - Best in Class Assays, Reagents and Clinical Lab Services - Invivoscribe

产品
- 产品概览
  Invivoscribe提供用于血液肿瘤学以及RUO检测的全系列标准化CE认证体外诊断cGMP产品、分析物特异性试剂（ASR）以及 DNA和RNA对照品。
  了解产品 ⟶
  搜索产品文件和 IFU ⟶
- 第二代测序
  CE-IVD
  Illumina®
  Thermo Fisher®
  RUO
  Illumina®
  Thermo Fisher®
  MRD 克隆性
- 伴随诊断 (CDx)
  LeukoStrat® CDx FLT3
  突变检测
  CE-IVD
  IVD (美国)
  IVD (日本)
- ABI 荧光检测
  CE-IVD
  克隆性
  FLT3
  RUO
  克隆性
  FLT3
  易位
- 凝胶检测
  CE-IVD
  克隆性
  FLT3
  易位
  RUO
  克隆性
  FLT3
  易位
- 对照品
  预混液对照品
  DNA对照品
  RNA对照品
  MRD对照品
- 试剂
  ASR
  酶
  Hi-Di甲酰胺
- 2024年产品目录
临床实验室服务
- 临床实验室服务概述
  Invivoscribe 的 Personalized Molecular Medicine^®（LabPMM^®）实验室可提供对患者护理至关重要的新型特有生物标志物的国际标准化测试服务。
  了解服务 ⟶
- 伴随诊断（CDx）检测
  CDx – 美国
  CDx – 德国
  CDx – 日本
- NGS 癌症Panel
  MyAML
  MyMRD
- MFC Panel
  血淋巴筛查Panel
  AML MRD检测
  慢性淋巴细胞白血病(CLL) MRD检测
- MRD NGS检测
  克隆性
  FLT3 ITD
  NPM1
- 克隆性NGS检测
  SHM
  IGH
  IGK
  TRG
  TRB
疾病
- 淋巴
  Mature B-cell
  Mature T-cell
  
  Lymphoma
  Lymphoma is a cancer that starts in cells that are part of the body’s immune system. Knowing which type of lymphoma you have is important because it affects your treatment options and your outlook (prognosis).
  
  LEARN MORE ⟶
- 髓系
  Myelodysplastic Syndromes (MDS)
  Acute Myeloid Leukemia (AML)
  Myeloproliferative Neoplasms (MPNs)
  
  Myeloma
  Multiple myeloma is a cancer of plasma cells. Normal plasma cells are found in the bone marrow and are an important part of the immune system.
  
  LEARN MORE ⟶
- 血液学测试菜单
  Browse our comprehensive menu of product & testing services.
  EXPLORE MENU ⟶
伙伴关系
- 伙伴关系概览
  一项加速药品批准流程的有效策略
  了解伙伴关系 ⟶
  GENE PANEL – 570 GENES & 370 RNAS
  MyHEME NGS panel identifies clinically actionable, pathogenic, and potentially pathogenic mutations.
  LEARN MORE ⟶
- 产品开发
  设计控制、生物信息学软件、识别和跟踪、定制开发和辅助 MRD 检测
  了解 ⟶
  CLIA
  MyMRD is a hotspot panel that detects all classes of variants identified in a precisely defined set of targets.
  LEARN MORE ⟶
- 制造
  符合cGMP标准、CE认证的IVD和CDx产品制造、检测开发以及对照品和试剂
  了解 ⟶
  Lymphoma
  Lymphoma is a cancer that starts in cells that are part of the body’s immune system. Knowing which type of lymphoma you have is important because it affects your treatment options and your outlook (prognosis).
  LEARN MORE ⟶
- LabPMM®
  临床实验室经验、国际标准化、全面Panel、辅助MRD检测和全球注册
  了解 ⟶
  Myeloma
  Multiple myeloma is a cancer of plasma cells. Normal plasma cells are found in the bone marrow and are an important part of the immune system.
  LEARN MORE ⟶
- 全球法规专业知识
  经认证的注册医疗器械制造商、多项CDx批准、经CE认证的IVD和上市许可持有人（MAH）
  了解 ⟶
  Search for:
科学
- 科学概览
  我们对能将个性化医疗与优质医疗保健服务相结合而作出的科学贡献引以为豪。
  了解我们的科学领域 ⟶
- 个性化医疗
  Personalized Molecular Medicine^®通过基因组学和患者特定信息为每名患者确定最佳治疗方案。
  了解个性化医疗 ⟶
出版物
- 精选刊物
  2020 年 11 月 17 日第二代测序克隆性检测在骨髓瘤微小残留病变常规评价中的应用
  查看出版物 ⟶
- 最新出版物
  2021 年 4 月 20 日基于第二代测序的 T 细胞受体γ基因重排诊断检测验证：从毛细管电泳过渡到第二代测序
  查看出版物 ⟶
  2020 年 11 月 17 日第二代测序克隆性检测在骨髓瘤微小残留病变常规评价中的应用
  查看出版物 ⟶
  查看所有出版物 ⟶
公司
搜索
- 搜索文章和出版物
  Search for:
- 搜索产品和服务
  搜索 ⟶
- 搜索产品资料和 IFU
  搜索⟶

Newsroom – Best in Class Assays, Reagents and Clinical Lab Servicesmarketing2021-09-02T23:19:14+00:00

Newsroom

Newsroom

LATEST PUBLICATIONS

Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients

marketing2021-02-11T21:58:45+00:00February 6th, 2020|

更多详细信息

Monitoring minimal residual disease in the bone marrow using next generation sequencing

marketing2021-02-11T22:00:56+00:00January 17th, 2020|

更多详细信息

Plasma Cell Myeloma Residual Disease Quantitation Using a Next-Generation Sequencing-Based IGH Clonal Rearrangement Assay with the Aid of a “Spike-in” Clonal Sequence

marketing2021-02-11T23:36:10+00:00November 13th, 2019|

更多详细信息

Clonally-Related CD5+ CLL/SLL and CD10+ high grade B-cell lymphoma suggests common neoplastic progenitor with branched disease evolution, with therapeutic implications

marketing2021-02-11T23:40:44+00:00October 15th, 2019|

更多详细信息

Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma

marketing2021-02-11T23:43:09+00:00October 1st, 2019|

更多详细信息

LATEST PRESS

Invivoscribe Submits the LeukoStrat CDx FLT3 Mutation Assay to Support Daiichi Sankyo Submission for Quizartinib in Japan

marketing2021-02-26T19:11:48+00:00November 19th, 2018|

更多详细信息

Invivoscribe® Receives Approval in Japan for its LeukoStrat® CDx FLT3 Mutation Assay to Assess Acute Myeloid Leukemia (AML) Patients Eligible for Treatment with Xospata® (gilteritinib fumarate)

marketing2021-02-26T19:12:02+00:00September 27th, 2018|

更多详细信息

Invivoscribe Announces a Regional “Center of Excellence” Reference Laboratory in Beirut to Offer Specialized Gene Panels

marketing2021-02-26T19:12:15+00:00May 9th, 2018|

更多详细信息

Invivoscribe Submits Pre-Market Approval Application in Japan and Panel Track Supplement in the US to Screen Acute Myeloid Leukemia (AML) Patients for FLT3 Mutations

marketing2021-02-26T19:12:23+00:00May 8th, 2018|

更多详细信息

Invivoscribe® Releases LymphoTrack® TRB Assay on MiSeq® and LymphoTrack® Minimal Residual Disease (MRD) Software

wmm2021-02-26T19:12:40+00:00November 7th, 2017|

更多详细信息

CONFERENCES